Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta to Get $15M from Monsanto in Gene Expression Deal

NEW YORK, Nov 28 –Rosetta Inpharmatics said Tuesday that it has entered a three-year deal to provide Monsanto with crop gene expression data.

The collaboration, which follows a pilot agreement between the two companies, is exclusive for the family of crops that includes corn, rice, and wheat.

Under terms of the agreement, Monsanto will pay Rosetta $15 million over a three-year period for the delivery of the data. Rosetta will also receive future payments, including royalties, as Monsanto develops and commercializes products, such as improved crops, as a result of the collaboration.

Among other activities, Rosetta will create a large database of gene expression profiles and will apply existing as well as newly developed computational tools to data analysis.

" By combining our sequence portfolio with Rosetta's expertise, we are creating a unique capability to further understand gene expression in crops," said Chris Burnley, vice president for genomics strategy and alliances at Monsanto in a statement.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.